Dietary natural products as emerging lipoprotein(a)‐lowering agents

Momtazi‐Borojeni, Amir Abbas; Katsiki, Niki; Pirro, Matteo; Banach, Maciej; Al-Rasadi, Khalid; Sahebkar, Amirhossein

doi:10.1002/jcp.28134

Cited by 31 publications

(16 citation statements)

References 218 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The deficiency of these nutrients in the body may increase the risk of developing a variety of conditions, including cardiovascular diseases [52,66]. Antioxidant supplementation has been extensively researched, but the findings remain inconclusive, especially in the case of vitamin E [13,67,68].…”

Section: Antioxidantsmentioning

confidence: 99%

Dietary Supplements—For Whom? The Current State of Knowledge about the Health Effects of Selected Supplement Use

Wierzejska

2021

IJERPH

View full text Add to dashboard Cite

Dietary supplements are products containing nutrients sold in various medicinal forms, and their widespread use may stem from the conviction that a preparation that looks like a drug must have therapeutic properties. The aim of this scoping review is to present what is known about the effects of using selected dietary supplements in the context of chronic diseases, as well as the risks associated with their use. The literature shows that the taking of vitamin and mineral supplements by healthy people neither lowers their risk of cardiovascular diseases nor prevents the development of malignancies. Many scientific societies recognize that omega-3 fatty acids lower blood triglycerides, but whether taking them prevents heart disease is less clear-cut. Taking weight loss supplements is not an effective method of fighting obesity. Often, some supplements are increasingly sold illegally, which is then also associated with the higher risk that they may be adulterated with banned substances, thus making them even more dangerous and potentially life-threatening. Supplements are necessary in cases of nutrient deficiency; however, even though prescription is not required, their use should be recommended and monitored by a physician.

show abstract

Section: Antioxidantsmentioning

confidence: 99%

Dietary Supplements—For Whom? The Current State of Knowledge about the Health Effects of Selected Supplement Use

Wierzejska

2021

IJERPH

View full text Add to dashboard Cite

show abstract

“…On the other hand, fibrates 95 , and most hormones (except growth hormone) 32,96 may reduce Lp(a) levels. Niacin 97 , mipomersen 98 , lomitapide 99 , proprotein convertase subtilisin kexin 9 (PCSK9) [100][101][102] and (cholesteryl transfer protein) CETP inhibitors 103 , aspirin 32 , antibodies to interleukin-6 32 , nutraceuticals [104][105][106][107] , tibolone 108 and ezetimibe 109 , also, decrease Lp(a) levels. Vitamin C 110 and bile acid sequestrants 111 have a neutral effect on plasma Lp(a) levels.…”

Section: Effect Of Hypolipidemic Treatment On Lp(a)mentioning

confidence: 99%

Lipoprotein(a): An update on its role in human health and disease

Koutsogianni¹,

Liberopoulos²,

Tselepis³

2021

JAPT

View full text Add to dashboard Cite

Over the past few years, there has been an undiminished interest on lipoprotein(a) [Lp(a)]. High Lp(a) levels have been proposed as an independent causal risk factor for atherosclerotic cardiovascular disease (CVD). The main question that remains to be answered, however, is the potential clinical benefit of Lp(a) reduction. This will contribute to the enrichment of our knowledge on the exact pathophysiological role of this lipoprotein. This narrative review aims to summarize currently available data on the structure, metabolism, and pathogenicity of Lp(a).

show abstract

“…(24.9-160) mg/dL after 2 months since statin treatment initiation in patients with FH and high Lp(a) levels who had a small molecular mass apo(a) (≤22 KIV 2 repeats), while no such effect was observed in patients with a large molecular mass apo(a) [73]. Based on this, the experts supported by the International Lipid Expert Panel (ILEP) suggested that in those with the baseline Lp(a) levels over 30 mg/dL and especially over 50 mg/dL the combination therapy of statins and ezetimibe and/or nutraceuticals with confirmed Lp(a)-reducation properties should be considered [72,74]. Statins are recommended in patients with elevated Lp(a) level not to reduce it but to decrease CVD risk [5].…”

Section: Managementmentioning

confidence: 99%